NL-OMON30587已完成2 期
A Phase 2 Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First Line Platinum-based Chemotherapy - Amrubicin in SCLC patients refractory to Platinum based Chemotherapy
PharmionCorporation0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Histological or cytological diagnosis of SCLC; extensive-disease (ED) at the time of study entry
- •- Refractory to first-line platinum-based chemotherapy (i.e., has received one prior platinum-based chemotherapy regimen) defined as one of the following:
- •a. Best response to first-line chemotherapy is radiographically documented progression (refractory disease)
- •b. Best response to first-line chemotherapy is radiographically documented response or stable disease, with subsequent documented progression during continuing chemotherapy (resistant relapse)
- •c. Documented progression within 90 days of completion of first-line chemotherapy (last dose of chemotherapy), regardless of best response to treatment (resistant relapse)
- •- At least 18 years of age
- •- ECOG Performance Status of 0, 1, or 2
- •- Measurable disease defined by RECIST criteria:
- •a. Measurable disease: The presence of at least one measurable lesion. If only one lesion is present, the neoplastic nature of the disease site should be confirmed by histology and/or cytology
- •b. Measurable lesion: Lesions that can be accurately measured in at least one dimension with the longest diameter ><= 20 mm using conventional techniques or ><= 10 mm using spiral CT scans. CT (including spiral CT) scans and MRI are the preferred methods of measurement; however, chest x-rays are acceptable if the lesions are clearly defined and surrounded by aerated lung. Clinically detected lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpable lymph nodes). For the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion is required.
- •- Adequate organ function including the following:
- •a. Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) ><= 1500 cells/uL, platelet count ><= 100,000 cells/uL and hemoglobin ><= 9 g/dL
- •b. Hepatic: bilirubin <<= 1.5 X ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <<= 3.0 X ULN.
- •c. Renal: serum creatinine < 2.0 mg/dL or calculated creatinine clearance > 60 mL/min
- •d. Cardiac: Left ventricular ejection fraction (LVEF) ><= 50% by MUGA or echocardiography (intra-patient reassessment of LVEF should be performed via the same method throughout the study).
- •- Negative serum pregnancy test at the time of enrollment for women of child-bearing potential. For men and women of child-producing potential, use of effective contraceptive methods during the study.
- •- Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments
排除标准
- •- Pregnant or nursing women
- •- Chest radiotherapy within the previous 28 days or other radiotherapy within the previous 14 days. Recovery from the acute toxic effects of radiation required prior to study enrollment. Measurable lesions that have been previously irradiated must be enlarging to be considered target lesions. Prior radiation therapy allowed to < 25% of the bone marrow.
- •- More than 1 prior chemotherapy regimen for SCLC.
- •- Prior anthracycline treatment.
- •- treatment with any investigational agent within 28 days or standard chemotherapy with 21 days prior to first dose. patients must have recovered from all acute adverse events of prior therapies, excluding alopecia
- •- Patients with second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 2 years previously with surgery and/or radiotherapy and no evidence of recurrence since that time).
- •- Concurrent severe or uncontrolled medical disease (i.e., active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •- Symptomatic central nervous system metastases. Patients with asymptomatic brain metastases are allowed. The patient must be stable after radiotherapy for >= 2 weeks and off corticosteroids for >= 1 week.
- •- History of interstitial lung disease or pulmonary fibrosis.
研究者
相似试验
进行中（未招募）
不适用
A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small CellLung Cancer that is Refractory or Progressive within 90 Days of Completion of First-LinePlatinum-based ChemotherapyExtensive Disease Small Cell Lung Cancer that is refractory or progressiveMedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-004785-14-NLCabrellis Pharmaceuticals Corporation64
进行中（未招募）
1 期
A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First-Line Platinum-based ChemotherapyExtensive Disease Small Cell Lung Cancer that is refractory or progressiveMedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-004785-14-GBCelgene Corporation63
已完成
2 期
Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.small cell lung cancerJPRN-UMIN000011055Kitasato University School of Medicine Department of Respiratory Medicine34
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCSmall Cell Lung Cancer (extensive stage)MedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-001956-11-NLCabrellis Pharmaceuticals Corporation85
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCSmall Cell Lung Cancer (extensive stage)MedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-001956-11-BECelgene International SAR97